DPAGT1: A Drug Target / Disease Biomarker (G1798)

Target Name: DPAGT1

NCBI ID: G1798

DPAGT1

Other Name(s): UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase | GlcNAc-1-P transferase 1 | CDG-Ij | DPAGT2 | CMSTA2 | GlcNAc-1-P transferase | GPT | GPT_HUMAN | D11S366 | Uridine diphosphoacetylglucosamine-dolichyl phosphate acetylglucosamine-1-phosphotransferase | UDP-D-N-acetylglucosamine N-acetylglucosamine 1-phosphate transferase | ALG7 | UAGT | N-acetylglucosamine-1-phosphate transferase | CMS13 | dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P tra | Dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P tra | UDP-acetylglucosamine-dolichol phosphate acetylglucosamine phosphotransferase | UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 | Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 | dolichyl-phosphate alpha-N-acetylglucosaminyltransferase | UDP-acetylglucosamine-dolichol phosphate acetylglucosamine-1-phosphotransferase | dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase) | DPAGT | DGPT | Chitobiosylpyrophosphoryldolichol synthase | Dolichol phosphate N-acetylglucosamine-1-phosphotransferase | UGAT | UDP-N-acetyl-D-glucosamine:dolichol phosphate N-acetyl-D-glucosamine-1-phosphate transferase | G1PT | dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 | CDG1J | UDP-GlcNAc:dolichyl-phosphate N-acetylglucosaminephosphotransferase

DPAGT1: A Drug Target / Disease Biomarker

DPAGT1, also known as drug-associated gene 1, is a gene that has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been linked to a range of clinical features, including increased risk of cancer and progressive neurodegeneration.

DPAGT1 is a gene that encodes a protein known as the decanate prospevtide receptor type 1 (DPP-R1). This protein plays a crucial role in cellular signaling and is involved in various physiological processes, including cell growth, differentiation, and survival.

Studies have suggested thatDPAGT1 may be involved in the development and progression of a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have found that individuals with the DPAGT1 mutation are at increased risk of developing lung cancer, breast cancer, and other cancers.

In addition to its potential role in cancer,DPAGT1 has also been linked to a range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by progressive neurodegeneration and are some of the most common causes of dementia and other cognitive impairments.

The link between DPAGT1 and neurodegenerative diseases is thought to be due to the fact that the protein is involved in the regulation of cellular signaling pathways that are involved in the development and progression of these conditions. For example, studies have shown thatDPAGT1 is involved in the production of amyloid peptides, which are thought to contribute to the development of Alzheimer's disease.

In addition to its potential role in cancer and neurodegenerative diseases,DPAGT1 has also been linked to an autoimmune disorder called rheumatoid arthritis. This condition is characterized by the production of autoantibodies, which can cause inflammation and damage to the joints.

The link between DPAGT1 and autoimmune disorders is thought to be due to the fact that the protein is involved in the regulation of cellular signaling pathways that are involved in the development and function of immune cells. For example, studies have shown thatDPAGT1 is involved in the production ofT cells, which are a crucial part of the immune system.

In conclusion,DPAGT1 is a gene that has been identified as a potential drug target for a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been linked to a range of clinical features, including increased risk of cancer and progressive neurodegeneration. Further research is needed to fully understand the role of DPAGT1 in these conditions and to develop effective treatments.

Protein Name: Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1

Functions: Catalyzes the initial step of dolichol-linked oligosaccharide biosynthesis in N-linked protein glycosylation pathway: transfers GlcNAc-1-P from UDP-GlcNAc onto the carrier lipid dolichyl phosphate (P-dolichol), yielding GlcNAc-P-P-dolichol

The "DPAGT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPAGT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets